- Investing.com
Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise mechanism of target engagement could unlock a series of high-value historically undruggable disease-driving genes in autoimmunity. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
T-Cell Revolution | Generation Bio pivots to T-cell driven autoimmune diseases, leveraging innovative ctLNP technology for siRNA delivery to potentially address undruggable targets |
Moderna Synergy | Explore the $1.8 billion potential in milestone payments from Generation Bio's collaboration with Moderna, advancing stealth LNP platform for immune cell targeting |
Financial Runway | With $185 million in cash, operations are funded into 2027, but market caution persists as the stock trades below cash position amid distant clinical timelines |
Future Prospects | Delve into Generation Bio's ambitious development timeline, with lead target nomination by mid-2025 and Phase 1 trials expected between late 2026 and early 2027 |
Metrics to compare | GBIO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGBIOPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.4x | −3.5x | −0.5x | |
PEG Ratio | −0.01 | −0.01 | 0.00 | |
Price/Book | 0.4x | 1.1x | 2.6x | |
Price / LTM Sales | 1.1x | 8.8x | 3.3x | |
Upside (Analyst Target) | - | 346.7% | 43.5% | |
Fair Value Upside | Unlock | 20.1% | 6.9% | Unlock |